Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
Klotho Neurosciences (NASDAQ: KLTO) has appointed Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its new Chief Operating Officer (COO). This strategic move aims to strengthen the company's leadership team and accelerate the development of its therapeutic candidates. Moriarty brings extensive experience in the pharmaceutical industry, including leadership roles at multinational companies and entrepreneurial success.
Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, highlighted Moriarty's expertise in operational management, strategic execution, and corporate culture development. Moriarty expressed enthusiasm for joining KLTO, citing its robust portfolio and promising cell and gene therapy platform. The company's focus is on developing breakthrough treatments for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, leveraging its exclusive worldwide license from the Autonomous University of Barcelona for treatments based on the secreted form of the Klotho gene (s-KL).
Klotho Neurosciences (NASDAQ: KLTO) ha nominato Peter Moriarty, co-fondatore di Shire Pharmaceuticals, come nuovo Chief Operating Officer (COO). Questa mossa strategica mira a rafforzare il team dirigenziale dell'azienda e ad accelerare lo sviluppo dei suoi candidati terapeutici. Moriarty porta con sé una vasta esperienza nell'industria farmaceutica, inclusi ruoli di leadership in aziende multinazionali e successi imprenditoriali.
Il Dr. Joseph Sinkule, Presidente, CEO e Fondatore di Klotho Neurosciences, ha evidenziato l'expertise di Moriarty nella gestione operativa, nell'esecuzione strategica e nello sviluppo della cultura aziendale. Moriarty ha espresso entusiasmo per l'ingresso in KLTO, citando il suo portafoglio robusto e la promettente piattaforma di terapia cellulare e genica. L'azienda si concentra sullo sviluppo di trattamenti innovativi per malattie neurodegenerative come la SLA, l'Alzheimer e il Parkinson, sfruttando la sua esclusiva licenza mondiale dall'Università Autonoma di Barcellona per trattamenti basati sulla forma secreta del gene Klotho (s-KL).
Klotho Neurosciences (NASDAQ: KLTO) ha nombrado a Peter Moriarty, cofundador de Shire Pharmaceuticals, como su nuevo Director de Operaciones (COO). Este movimiento estratégico tiene como objetivo fortalecer el equipo de liderazgo de la empresa y acelerar el desarrollo de sus candidatos terapéuticos. Moriarty aporta una amplia experiencia en la industria farmacéutica, incluidos roles de liderazgo en empresas multinacionales y éxitos empresariales.
El Dr. Joseph Sinkule, Presidente, CEO y Fundador de Klotho Neurosciences, destacó la experiencia de Moriarty en gestión operativa, ejecución estratégica y desarrollo de cultura corporativa. Moriarty expresó su entusiasmo por unirse a KLTO, citando su sólido portafolio y su prometedora plataforma de terapia celular y génica. La empresa se enfoca en desarrollar tratamientos innovadores para enfermedades neurodegenerativas como la ELA, el Alzheimer y el Parkinson, aprovechando su licencia mundial exclusiva de la Universidad Autónoma de Barcelona para tratamientos basados en la forma secretada del gen Klotho (s-KL).
Klotho Neurosciences (NASDAQ: KLTO)는 Shire Pharmaceuticals의 공동 창립자인 Peter Moriarty를 새로운 Chief Operating Officer (COO)로 임명했습니다. 이 전략적 결정은 회사의 리더십 팀을 강화하고 치료 후보 개발을 가속화하는 것을 목표로 합니다. Moriarty는 다국적 회사에서의 리더십 역할과 기업가적 성공을 포함한 제약 산업에서 광범위한 경험을 가지고 있습니다.
Klotho Neurosciences의 의장, CEO 및 창립자인 Dr. Joseph Sinkule는 Moriarty의 운영 관리, 전략 실행 및 기업 문화 개발에 대한 전문성을 강조했습니다. Moriarty는 KLTO에 합류하게 된 것에 대해 열정을 표명하며, 탄탄한 포트폴리오와 유망한 세포 및 유전자 치료 플랫폼을 언급했습니다. 이 회사는 Klotho 유전자(s-KL)의 분비 형태를 기반으로 한 치료법에 대한 바르셀로나 자치대학의 독점 글로벌 라이센스를 활용하여 ALS, 알츠하이머병 및 파킨슨병과 같은 신경퇴행성 질환에 대한 혁신적인 치료제를 개발하는 데 중점을 두고 있습니다.
Klotho Neurosciences (NASDAQ: KLTO) a nommé Peter Moriarty, co-fondateur de Shire Pharmaceuticals, comme nouveau Directeur des opérations (COO). Ce mouvement stratégique vise à renforcer l'équipe de direction de l'entreprise et à accélérer le développement de ses candidats thérapeutiques. Moriarty apporte une vaste expérience dans l'industrie pharmaceutique, y compris des rôles de direction au sein d'entreprises multinationales et des succès entrepreneuriaux.
Le Dr Joseph Sinkule, Président, CEO et fondateur de Klotho Neurosciences, a souligné l'expertise de Moriarty en gestion opérationnelle, en exécution stratégique et en développement de la culture d'entreprise. Moriarty a exprimé son enthousiasme à rejoindre KLTO, évoquant son portefeuille solide et sa plateforme prometteuse de thérapie cellulaire et génique. L'entreprise se concentre sur le développement de traitements révolutionnaires pour des maladies neurodégénératives telles que la SLA, Alzheimer et Parkinson, en s'appuyant sur sa licence mondiale exclusive de l'Université Autonome de Barcelone pour des traitements basés sur la forme sécrétée du gène Klotho (s-KL).
Klotho Neurosciences (NASDAQ: KLTO) hat Peter Moriarty, Mitbegründer von Shire Pharmaceuticals, zu seinem neuen Chief Operating Officer (COO) ernannt. Dieser strategische Schritt zielt darauf ab, das Führungsteam des Unternehmens zu stärken und die Entwicklung seiner therapeutischen Kandidaten zu beschleunigen. Moriarty bringt umfangreiche Erfahrung in der Pharmaindustrie mit, darunter Führungspositionen in multinationalen Unternehmen und unternehmerische Erfolge.
Dr. Joseph Sinkule, Vorsitzender, CEO und Gründer von Klotho Neurosciences, hob Moriartys Expertise in operativer Verwaltung, strategischer Umsetzung und Entwicklung der Unternehmenskultur hervor. Moriarty äußerte seine Begeisterung über den Eintritt in KLTO und verwies auf das starke Portfolio und die vielversprechende Zell- und Gentherapieplattform. Das Unternehmen konzentriert sich darauf, bahnbrechende Behandlungen für neurodegenerative Erkrankungen wie ALS, Alzheimer und Parkinson zu entwickeln und dabei die exklusive weltweite Lizenz der Autonomen Universität Barcelona für auf der sekretierenden Form des Klotho-Gens (s-KL) basierende Behandlungen zu nutzen.
- Appointment of industry veteran Peter Moriarty as COO, bringing extensive pharmaceutical experience
- Exclusive worldwide license for treatments based on the Klotho gene, backed by patents in the U.S., Europe, and China
- Potential for breakthrough treatments in neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's
- None.
KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO).
Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, welcomed Moriarty to the leadership team: “We are thrilled to have Peter join Klotho Neurosciences as COO. His extensive experience across the pharmaceutical industry, both in the U.S. and globally, will be instrumental as we move forward. Peter has a remarkable track record, including leadership roles at multinational pharmaceutical companies in the US and internationally and an entrepreneurial career highlighted by his co-founding of Shire Pharmaceuticals. He brings a wealth of expertise in operational management, strategic execution, and cultivating corporate culture—assets that will be critical as we advance our pipeline of innovative therapies.”
Peter Moriarty expressed enthusiasm for his new role: “I am excited to now be part of the team at Klotho Neurosciences, a company I became familiar with during my time as a consultant. What attracted me was its robust portfolio and the significant promise of its cell and gene therapy platform. I believe Klotho Neurosciences is uniquely positioned to develop breakthrough treatments for neurodegenerative diseases like ALS, Alzheimer’s, and Parkinson’s. With the exclusive worldwide license from the Autonomous University of Barcelona, backed by patents across the U.S., Europe, and China, the company is set to revolutionize treatments based on the secreted form of the Klotho gene (s-KL). This could be a true game changer in treating neurodegenerative and age-related disorders, and I’m eager to contribute to this groundbreaking work.”
Klotho Neurosciences is committed to harnessing the potential of gene-based therapies to target the root causes of neurodegenerative diseases and age-related disorders. With Moriarty’s pharmaceutical experience and leadership skills, the company is poised to accelerate the development of its therapeutic candidates.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company pioneering the development of innovative, disease-modifying cell and gene therapies using a patented secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
Who is the new COO of Klotho Neurosciences (KLTO)?
What is Klotho Neurosciences (KLTO) focusing on developing?
What exclusive license does Klotho Neurosciences (KLTO) hold?
How might Peter Moriarty's appointment impact Klotho Neurosciences (KLTO)?
